Table of contents
- Latest Vimovo Lawsuit Updates
- September 2, 2025: Pending MDL Report Lists PPI Litigation
- October 3, 2023: AstraZeneca Settles Nexium and Prilosec Claims
- June 26, 2023: Court Sets Deadline to Add Defendants
- February 25, 2021: FDA Reviews Pediatric Reports on Vimovo
- July 6, 2017: FDA Approves Adolescent Use of Vimovo
- What Is Vimovo?
- Who May Be Affected?
- Reported Injuries or Damages
- Evidence to Preserve
- Filing Deadlines
- Frequently Asked Questions
- Does Vimovo Contain the Same Drug as Nexium?
- Who Makes Vimovo?
- What Does the Research Say About Vimovo and Kidney Problems?
- Has Vimovo Been Recalled?
- What Kidney Warnings Does the Label Carry?
Vimovo, the prescription tablet that combines naproxen and esomeprazole magnesium, carries FDA label warnings for kidney problems. In related lawsuits, some users said the PPIs Nexium and Prilosec caused kidney damage.
No Vimovo lawsuit, class action or MDL exists. The related proton pump inhibitor litigation, MDL 2789 in New Jersey federal court, covers other PPI brands. AstraZeneca settled its Nexium and Prilosec claims for $425 million in October 2023.
The FDA approved Vimovo in 2010 for adults with arthritis who need naproxen and are at risk of gastric ulcers. Kidney problems are a labeled warning, and any question about your own symptoms belongs with your prescriber.
Latest Vimovo Lawsuit Updates
September 2, 2025: Pending MDL Report Lists PPI Litigation
On September 2, 2025, the Judicial Panel on Multidistrict Litigation issued a pending-docket report. The report listed MDL 2789, In re Proton-Pump Inhibitor Products Liability Litigation (No. II), with 11,336 actions pending [1].
The MDL sits in the District of New Jersey, before Judge Claire C. Cecchi. The report does not name Vimovo.
October 3, 2023: AstraZeneca Settles Nexium and Prilosec Claims
On October 3, 2023, AstraZeneca agreed to pay $425 million to settle US product liability lawsuits over Nexium and Prilosec, Bloomberg Law reported [2].
The settlement resolves litigation in New Jersey and Delaware courts. It is a company agreement, and a settlement does not by itself show that a drug caused harm.
June 26, 2023: Court Sets Deadline to Add Defendants
On June 26, 2023, Judge Claire C. Cecchi issued Case Management Order No. 101 in the proton-pump inhibitor MDL [3]. The order set a deadline for plaintiffs to amend their pleadings.
The deadline applied to adding two GlaxoSmithKline consumer entities as defendants. The MDL coordinates claims alleging personal injury and wrongful death from use of one or more PPIs.
February 25, 2021: FDA Reviews Pediatric Reports on Vimovo
On February 25, 2021, the FDA pediatric review of Vimovo was published [4]. It covered reports received from April 30, 2010 through June 7, 2020.
The review identified no new safety signals. It found no increased severity or frequency of labeled adverse events. It found no deaths directly associated with naproxen/esomeprazole magnesium.
July 6, 2017: FDA Approves Adolescent Use of Vimovo
On July 6, 2017, the FDA approved a revised Vimovo label [5]. It added adolescents 12 and older weighing at least 38 kg with juvenile idiopathic arthritis.
Vimovo had first been approved for adults on April 30, 2010. The 2017 change extended its use to adolescents with this form of arthritis.
What Is Vimovo?
According to the FDA label, Vimovo combines naproxen, an NSAID, with esomeprazole magnesium, a proton pump inhibitor. It is for people who need naproxen for arthritis. The esomeprazole lowers the risk of naproxen-associated gastric ulcers.
A PMC review of Vimovo says the tablet releases esomeprazole first in the stomach and naproxen later in the small intestine, where it dissolves [6].
Who May Be Affected?
Vimovo is prescribed to adults and teens 12 and older who weigh at least 38 kg. That includes people with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or juvenile idiopathic arthritis.
The same FDA label warns of renal toxicity from the naproxen in the tablet. It also warns of acute interstitial nephritis, a kidney problem seen in patients on PPIs including Vimovo.
People who took Vimovo and later had kidney disease may match these circumstances. A lawyer’s individual review of your records can say whether you may have a claim.
Reported Injuries or Damages
Users in the related PPI lawsuits said Nexium and Prilosec harmed their kidneys. That is an allegation and not a finding. It concerns drugs other than Vimovo.
A 2017 PLOS ONE study by Pello Lazaro and colleagues looked at PPI use in patients with chronic coronary artery disease [7]. It measured heart outcomes, not kidney outcomes.
A 2016 case report in Medicine told of the first reported case of rhabdomyolysis after one intravenous dose of esomeprazole [8]. The authors wrote that the dose “might be associated with rhabdomyolysis, directly or indirectly.”
One case report does not prove that Vimovo caused a particular injury. Reports like these show a possible link and not a cause. Raise any kidney symptoms with your doctor.
Evidence to Preserve
If you took Vimovo and had kidney problems, keep these records in one safe place:
- Prescription and pharmacy records that show Vimovo or esomeprazole use and the dates you took it.
- The pill bottle or pharmacy label, kept with the fill date for each prescription.
- Medical records and lab results that show your kidney function before and after treatment.
- A list of the other medicines you took during the same period, with doses.
- Physician notes, receipts and insurance claims linked to your Vimovo treatment.
- Any messages with the manufacturer or your prescriber about side effects.
Filing Deadlines
Filing deadlines come from state law. They vary with where you live and when your injury and diagnosis happened. Some states start the clock at diagnosis.
A missed deadline can end a Vimovo claim, however strong the facts look. Ask a lawyer about your deadline promptly.
Frequently Asked Questions
Does Vimovo Contain the Same Drug as Nexium?
Vimovo contains esomeprazole magnesium, the same active ingredient as Nexium. Vimovo adds naproxen, an NSAID, in the same tablet, and the FDA’s pediatric review says its application relies on Nexium.
Who Makes Vimovo?
Horizon Medicines, LLC makes Vimovo as its FDA applicant, according to the FDA’s 2021 pediatric review. No Vimovo defendant is named in the related PPI MDL 2789, which covers other brands.
What Does the Research Say About Vimovo and Kidney Problems?
The research on Vimovo and kidney problems starts with studies of PPIs in general. The PLOS ONE study followed 706 patients with coronary artery disease. It associated PPI use with an increased incidence of heart failure and death, not kidney outcomes. Its authors say further studies are needed.
Has Vimovo Been Recalled?
Vimovo has not been recalled, and no recall notice names it. If you have questions about your own Vimovo prescription or a kidney symptom, ask the prescribing doctor or a pharmacist.
What Kidney Warnings Does the Label Carry?
The kidney warnings on the Vimovo label include renal papillary necrosis and other renal injury from long-term NSAID use. The label says to discontinue Vimovo if acute interstitial nephritis develops, which may occur at any point during PPI therapy.